0 41

Cited 5 times in

Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study)

Authors
 Sun A. Yoon  ;  Byoung G. Han  ;  Sung G. Kim  ;  Sang Y. Han  ;  Young I. Jo  ;  Kyung H. Jeong  ;  Kook H. Oh  ;  Hyeong C. Park  ;  Sun H. Park  ;  Shin W. Kang  ;  Ki R. Na  ;  Sun W. Kang  ;  Nam H. Kim  ;  Young H. Jang  ;  Seong H. Shin  ;  Dae R. Cha 
Citation
 Diabetes Obesity & Metabolism, Vol.19(4) : 590-598, 2017 
Journal Title
 Diabetes Obesity & Metabolism 
ISSN
 1462-8902 
Issue Date
2017
MeSH
Aged ; Albuminuria/drug therapy* ; Albuminuria/etiology ; Albuminuria/urine ; Blood Glucose/drug effects ; Body Weight/drug effects ; Creatinine/urine ; Diabetes Mellitus, Type 2/complications* ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/urine ; Diabetic Nephropathies/complications* ; Diabetic Nephropathies/drug therapy ; Diabetic Nephropathies/urine ; Double-Blind Method ; Female ; Glycated Hemoglobin A/drug effects ; Humans ; Hypoglycemic Agents/administration & dosage* ; Male ; Middle Aged ; Piperidones/administration & dosage* ; Pyrimidines/administration & dosage* ; Republic of Korea ; Treatment Outcome
Keywords
DPP-IV inhibitor ; diabetic nephropathy ; phase III study ; type 2 diabetes mellitus
Abstract
AIMS: This multicentre, randomized, double-blind study investigated the efficacy and safety of gemigliptin in Korean type 2 diabetes mellitus (T2DM) patients with moderate to severe renal impairment (RI). METHODS: The study comprised a 12-week main part and a 40-week extension. We report here the results from the main part. In total, 132 patients were randomized to receive gemigliptin (n = 66) or placebo (n = 66). Changes in glycated haemoglobin (HbA1c; primary endpoint), other glycaemic control parameters (fasting plasma glucose, glycated albumin and fructosamine), lipid profiles, renal function parameters and safety profiles were evaluated. RESULTS: Baseline characteristics were comparable between the groups (mean HbA1c, 8.4% [68 mmol/mol]; age, 62.0 years; duration of type 2 diabetes, 16.3 years; estimated glomerular filtration rate, 33.3 mL/min/1.73 m2 ). At Week 12, the adjusted mean change ± standard error in HbA1c with gemigliptin was -0.82% ± 0.14% (-8.9 ± 1.5 mmol/mol), whereas it was 0.38% ± 0.14% (4.2 ± 1.5 mmol/mol) with placebo (significant between-group difference, P  < .001). Other glycaemic control parameters showed beneficial changes as well. Body weight change (gemigliptin, -0.3 kg; placebo, -0.2 kg) was not significant. In the gemigliptin group, the mean decrease in urinary albumin creatinine ratio (UACR) was significant, both in patients with microalbuminuria (-41.9 mg/g creatinine, P  = .03) and macroalbuminuria (-528.9 mg/g creatinine, P  < .001). Drug-related adverse events were similar with gemigliptin and placebo (15% and 12%, respectively). CONCLUSIONS: A 12-week treatment with gemigliptin improved glycaemic control and provided UACR reduction in T2DM patients with moderate to severe RI. Gemigliptin was well tolerated, with no additional risk of hypoglycaemia and change in body weight.
Full Text
https://onlinelibrary.wiley.com/doi/full/10.1111/dom.12863
DOI
10.1111/dom.12863
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
박형천(Park, Hyeong Cheon) ORCID logo https://orcid.org/0000-0002-1550-0812
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/165922
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse